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Juvenile Paget’s disease (JPD) is a rare autosomal-recessive 
condition. It is diagnosed in young children and charac-
terized by a generalized increase in bone turnover, bone 
pain, and skeletal deformity. Our patient was diagnosed 
after a pathological fracture when she was 11 years old. 
When we first examined her at the age of 30 she had bone 
pain and deformity in both the femur and tibia. Serum al-
kaline phosphatase (ALP) level, radiology, bone scintigra-
phy, and densitometry were monitored. Next generation 
sequencing (NGS) technology, namely semiconductor se-
quencing, was used to determine the genetic background 
of JPD. Seven target genes and regions were selected and 
analyzed after literature review (TM7SF4, SQSTM1, TNFRS-
F11A, TNFRSF11B, OPTN, CSF1, VCP). No clear pathogen-
ic mutation was found, but we detected missense poly-
morphisms in CSF1 and TM7SF4 genes. After treatment 
with zoledronic acid, infusion bone pain and ALP level 
decreased. We can conclude that intravenous zoledron-
ic acid therapy is effective and safe for suppressing bone 
turnover and improving symptoms in JPD, but the long-
term effects on clinical outcomes are unclear. Our findings 
also suggest that NGS may help explore the pathogenesis 
and aid the diagnosis of JPD.
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Juvenile Paget’s disease (JPD) is a rare genetic bone dis-
ease, with approximately 60 cases reported in total world-
wide (1). In JPD, the function of the key proteins regulating 
osteoclast differentiation or function is affected. but like in 
Paget’s disease of bone (PDB), the exact pathomechanism 
is not understood. The genetic predisposition influences 
the function of bone cells. Though the gene candidates of 
the disease have not been identified yet, it is transmitted 
as an autosomal recessive trait (2,3). In most cases, there is 
a deficiency of the protein osteoprotegerin, leading to the 
clinical manifestations of the disease (3). No other affected 
genes have been identified yet.
Some patients are asymptomatic, whereas others develop 
complications (4). JPD manifests in infancy or childhood, 
characterized by greatly accelerated and disorganized 
bone turnover (typically at focal areas), manifesting in bone 
deformities, pain secondary to fractures, osteopenia of the 
long bones, corticomedullary indistinctness, coarsening of 
the trabecular bone, growth retardation, deafness due to 
cochlear involvement, and nerve compression syndromes 
(2-4). Although clinically JPD has some similarities to PDB, 
the early age at onset and marked bone deformities can 
result in different pathomechanisms.
We present a rare case of mild form of JPD with a genetic 
analysis – using a next generation sequencing technique 
– of seven target genes and regions of PDB. With the ap-
pearance of next-generation sequencing (NGS) machines, 
molecular biology reached a new revolutionary phase. 
This new technology combines high performance with 
much less expensive operation costs. Furthermore, we de-
signed a novel approach to genetic testing in which we 
simultaneously sequenced the whole coding regions of 
the affected genes at the same time. Our approach was 
based on using an IonTorrent PGM from Life Technologies 
(Carlsbad, CA, USA). This benchtop sequencer belongs to 
the semiconductor sequencer family. It acquires the DNA 
sequence by detecting electric impulses created by the 
release of H+ -ions in its microchip. The solution that con-
tains the H+-ions serves as a gate electrode of a transistor, 
a so called ion sensitive field electricity transistor (ISFET). 
This signal combined with cyclic addition of dNTP-s can 
be processed by the sequenator’s software as the incor-
poration of a nucleic acid, and several cycles will provide 
the sequence of the DNA in question. It is possible to bar-
code the samples with a sequence by which the software 
can differentiate between them. This is a great tool to se-
quence several samples at the same time, reducing the 
sequencing costs.
We used the IonTorrent PGM (Life Technologies) to exam-
ine all genes known to play a role in the development of 
the different subtypes of Paget’s disease. Also, we treated 
our patient with zoledronate therapy, which makes this the 
second study to describe administration of such a medica-
tion in juvenile Paget’s disease (1).
Patient, materiaLS, anD methoDS
Case report
We present a case of a 30-year-old woman with JPD. Her 
parents, grandparents, and two siblings had no history of 
any bone disease. They had normal alkaline phosphatase 
(ALP) level and had no known clinical bone abnormalities. 
However, we were unable to submit them to genetic test-
ing. When the patient was 11 years old, she had a non-trau-
matic fracture on the left tibia. At that time, the serum ALP 
activity was elevated to 414 U/L. The bowing deformities 
of her lower extremities were noted and the diagnosis of 
JPD was made. Her bone age was normal. She received cal-
citonin therapy for six months and according her mother 
she tolerated the injections without apparent side effects 
and seemed to have less pain in her lower limbs. After this, 
she had no clinical progression for nineteen years.
In May 2011, she was referred to the National Institute of 
Rheumatology and Physiotherapy suffering from fatigue 
and bone pain in her lower extremities. Physical examina-
tion showed normal vital signs, weight of 47 kg, and height 
of 156 cm. She had marked scoliosis of the lumbar spine 
and the lower limbs showed anterior bowing of both fem-
ora and tibias (Figure 1). She had no difficulties in hear-
ing and no eye or neurological problems. The study was 
approved by the National Institute of Rheumatology and 
Physiotherapy Committee of Research Ethics, and the pa-
tient gave written informed consent.
mutation analysis – ion torrent sequencing
Genomic DNA was isolated from 200 µL of peripheral 
blood using Reliaprep Blood gDNA Miniprep System (Pro-
mega, Fitchburg, WI, USA). Target genes and regions (DC-
STAMP, SQSTM1, TNFRSF11A, TNFRSF11B, OPTN, CSF1, VCP) 
(Table 1) were selected after carefully reviewing the litera-
ture (5-8) and the information in NIH Genetic Home Refer-
ence site (http://ghr.nlm.nih.gov/).
Amplicons were designed using the AmpliSeq Designer 
1.2 software (Life Technologies), targeting the complete 
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coding sequence of each gene of interest (design ID: 
IAD27911). Amplicon library was prepared using Ion Amp-
liSeq Library Kit 2.0 (Life Technologies). The emulsion poly-
merase chain reaction (PCR) with Ion Sphere Particles (ISPs) 
was run using automated template preparation system 
(Ion One Touch, Life Technologies). Non-templated beads 
were removed in a semi-automated enrichment step us-
ing Ion One Touch ES instrument (Life Technologies). ISPs 
were loaded into Ion 314 chip and the sequencing runs 
were performed with 260 flows on Ion Torrent Personal Ge-
nome Machine (PGM).
Data from the Ion Torrent run were analyzed using the plat-
form specific pipeline software, Torrent Suite v3.2.1 (Life 
Technologies) to base-calling, trim adapter and primer se-
quences, and to filter out poor quality reads. The variants 
were reviewed and annotated using dbSNP (http://www.
ncbi.nlm.nih.gov/projects/SNP/) database. Missense vari-
ants were validated by Sanger sequencing. The Sanger se-
quences data were investigated using ABI Sequence Scan-
ner 1.0 (Life Technologies). The amplification primers were 
the following: rs1058885-F: TCCCAGAAGAAGCCTCTGGA, 
rs1058885-R: GCAGGTGGAAGACAGACTCC, rs3802204-F: 
actgagtacaaaaatggcatgca, rs3802204-R: acaccaccatcttg-
gcctta.
The sequencing run achieved 196 777 reads, generat-
ing 18.1Mb of sequencing data. The average base cover-
age depth was 1037 and the 1-fold target coverage was 
97.11%, and the 100-fold coverage was 91.83% with a 
mean raw accuracy of 99%. The uniformity of coverage 
was 87.52%
reSuLtS
Laboratory, radiographic, and densitometry findings
Six months before the patient was referred to the hospi-
tal, she had rapid bone turnover with elevated ALP levels 
of 570 U/L (reference range: 98-280 U/L), which after the 
bisphosphonate treatment declined to 334 U/L. The serum 
level of osteocalcin was 72 pg/mL (reference range: 11-43 
pg/mL) and after treatment it declined to 25 pg/mL. Beta-
crosslaps were elevated to 1347 pg/mL (reference range: 
10-594) and declined to 731 pg/mL. At the first examina-
tion in our center, vitamin D deficiency was diagnosed. The 
25 OH vitamin D3 level was decreased to 7 ng/mL (refer-
ence range: 23-60 ng/mL), and after vitamin D supplemen-
tation it increased to 57 ng/mL. Serum calcium and phos-
phate levels were within the reference range.
The x-ray tests showed involvement of both lower ex-
tremities – bowed long bones with cortical thinning and 
hypomineralization of the trabecular bone. Bone scan re-
vealed increased uptake in the right and left femur and tib-
ia. Also, increased radiotracer uptake was observed in the 
left clavicle. The DXA scan showed osteopenia, with a lum-
bar spine area BMD (Bone Mineral Density) T score -1.4 and 
femoral neck BMD T score -1.6.
mutation analysis – ion torrent sequencing
The leukocyte DNA analysis showed no known muta-
tions of the examined genes, however we detected 
FiGure 1. Counterclockwise from the top: photograph show-
ing deformity of the left and right tibia. radiograph of the left 
tibia showing osteosclerosis and osteolysis. radionuclide bone 
scan showing increased tracer uptake in both femur and tibia.
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missense single nucleotide polymorphisms at exon-6 of 
CSF1 and exon-3 of TM7SF4 genes, which resulted in an 
amino acid change (Table 2).
The CSF1 L408P leucin to prolin amino acid change result-
ed in similar physico-chemical properties. Both residues 
were medium size and hydrophobic. The TMSF4 D349G 
aspartic acid to glycin amino acid change located in the 
cytoplasmic topological domain resulted in a change from 
an acidic polar amino acid to an aliphatic non-polar one. 
The total number of identified genetic variants in the tar-
geted genomic region was 27 (Table 3) and based on the 
protein effect and allele frequency we excluded 25 variants 
from further investigations.
The presence of these polymorphisms has not been re-
ported so far either in JPD or PDB. We also genotyped 5 
other genes that are mostly connected with PDB (SQSTM1, 
TNFRSF11A, TNFRSF11B, OPTN, VCP). The seven target 
genes and regions were selected after a careful review of 
the literature on PDB (5-8). We did not detect any aberra-
tion in the examined genes and regions. Previous studies 
(5,6) have reported alterations only in the TNFRSF11B gene 
in JPD patients, independently of the phenotype of the 
disease. We did not detect these mutations in our patient.
treatment
The patient received one treatment with zoledronic acid 
(Novartis Pharmaceuticals Corporation, Basel, Switzerland) 
5 mg intravenously. Due to vitamin D deficiency, cholecal-
ciferol 40 000 IU/d was given for 5 days and then 2000 IU 
orally each day as maintenance therapy. She had a sub-
stantial response to the treatment, but did not achieve a 
full remission. One year after zoledronic acid treatment, the 
deformity in the lower limbs did not progress and no more 
fractures occurred. However, this period was sufficiently 
long for a meaningful evaluation. After zoledronic treat-
ment, serum calcium and phosphate levels were within 
the reference ranges.
DiSCuSSion
We demonstrated that NGS may help in the diagnosis of 
JPD. JPD, like PDB, is primarily caused by disregulation of 
osteoclast function. Clinically, JPD has some similarities to 
PDB, so it made sense to analyze the genes that had a role 
in the pathomechanism of PDB. Nevertheless, JPD should 
not be considered as a juvenile form of PDB. Increased evi-
dence (5,6) suggests that PDB is caused by a combination 
of rare, high-penetrance variants in genes like SQSTM1 and 
TNFRSF11B, and common variants in genes such as CSF1, 
TNFRSF11A, and TM7SF4 (also called DCSTAMP). Genome-
wide association studies (GWAS) also revealed the role of 
other genes, such as OPTN, VCP, and regions like rs9533156, 
rs9525641, rs3742257, rs3102735 in the pathogenesis of 
PDB (5,6). These target genes and regions were selected 
and analyzed in our study.
In our patient we did not detect any mutation affecting 
the SQSTM1 and TNFRSF11B genes, which play key roles in 
osteoclast differentiation and function. Former JPD case re-
ports (9,10) have found only mutations within TNFRSF11B 
gene, which encodes OPG, an endogenous inhibitor of os-
teoclast activity (9-12). Whyte et al (13) reported 2 unrelat-
ed patients with deletion of the TNFRSF11B gene, whose 
serum OPG levels were undetectably low. Cundy et al de-
scribed a homozygous 3-bp deletion in TNFRSF11B. Next 
to the 5 insertion/deletion mutations in TNFRSF11B, 3 mis-
taBLe 1. target genomic regions and coverages
target 
identifiers
target 
length (bp)
missed by the assay 
designer algorithm (bp) Coverage (%)
TM7SF4* 1413 0 100
SQSTM1 1372 22  98.4
TNFRSF11A 1851 192  89.63†
TNFRSF11B 1206 0 100
OPTN 1734 57  96.71
CSF1 2342 61  97.4
VCP 2421 46  98.1
rs9533156 100 0 100
rs9525641 100 0 100
rs3742257 100 0 100
rs3102735 100 0 100
*also known as DCStamP.
†the uncovered region of tnFrSF11a was analyzed by conventional 
polymerase chain reaction and agarose gel electrophoresis in order to 
find known deletions/duplications.
taBLe 2. Variants with amino acid changes
Gene type Ploidy referent Variant annotation Location amino acid change SiFt score
CSF1 SNP Het T C rs1058885 EXON-6 L408P 0.17
TM7SF4† SNP Het A G rs3802204 EXON-3 D349G 0.53
*SiFt – a tool that uses sequence homology to predict whether a substitution affects protein function (Sorts intolerant From tolerant substitutions); 
SnP – single nucleotid polymorphism
†also known as DCStamP.
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sense TNFRSF11B mutations were identified, all being loss-
of-function mutations (9). Recently, Saki et al (1) reported 
a kindred with TNFRSF11B mutation, which was indepen-
dent of JPD phenotype.
We detected single nucleotide polymorphisms at exonal 
region of both CSF1 and TM7SF4 genes. The CSF1 gene 
encodes a macrophage colony-stimulating factor, which 
is essential for osteoclast and macrophage differentiation 
(12,14). Common genetic variants at the CSF1 gene were 
first identified in a GWAS as a predisposing factor for PDB 
(6). The mechanisms by which genetic variants of the CSF1 
locus cause PDB or JPD remain unclear, but it seems likely 
that they act by regulating expression of CSF1, given the 
fact that serum M-CSF levels in affected patients are in-
creased (2,6). A gene required for fusion of osteoclast pre-
cursors is the TM7SF4 gene. This gene encodes the den-
dritic cell-specific transmembrane protein (also referred as 
DCSTAMP), which takes part in the fusion and multi-nucle-
ation of osteoclasts. The role of the TM7SF4 gene region in 
the development of PDB has been recently confirmed in 
an extended GWAS in PDB (6).
Our study has some limitations. Certain parts of the cod-
ing sequences of the targeted genes were not covered by 
the custom AmpliSeq design, thus these regions were ex-
cluded from the sequencing and variant finding. The first 
exon of TNFRSF11A gene was analyzed manually (prim-
er-F: CCGCTGAGGCCGCGGCGCCC, primer-R: CTCCGCTC-
CCCAAAACTCCG), because 10.47% of the coding region 
was missed by the Ion Torrent sequencing design. We se-
quenced all the regions known to be linked to the Paget’s 
disease and we did not find any of the known mutations. 
The effects of the found intronic variants and the function-
al effect of the found missense variants need to be clarified 
in further studies. The genetic background of JPD is still not 
taBLe 3. List of all identified variants
Chromo-
some Position
target 
identifier type Ploidy referent Variant
Variant 
frequency Coverage dbSnP
Coding 
variant
Protein 
effect
maF/minor 
alleleCount
chr1 110458234 CSF1 SNP Hom G A 100.00 395 rs2275123 c.163-22G>A - A = 0.213/465
chr1 110466338 CSF1 SNP Het C A 53.75 480 rs333970 c.1095C>A p.Thr365 = A = 0.447/977
chr1 110466466 CSF1 SNP Het T C 37.40 131 rs1058885 c.1223T>C p.Leu408Pro C = 0.426/930
chr1 110466709 CSF1 SNP Hom T C 98.13 319 rs333971 c.1466T>C p.Phe191Ser t = 0.0032/16
chr1 110466810 CSF1 SNP Het C A 50.53 95 rs2229166 c.1567C>A p.Arg225 = A = 0.309/674
chr1 110467745 CSF1 SNP Hom A G 99.84 621 rs333972 c.1623-24A>G - t = 0.0032/16
chr5 179260153 SQSTM1 SNP Het C T 52.59 424 rs4935 c.624C>T p.Asp208 = C = 0.316/691
chr5 179260213 SQSTM1 SNP Het G A 40.28 432 rs4797 c.684G>A p.Arg228 = G = 0.419/916
chr8 105367096 TM7SF4 SNP Hom T C 99.87 1510 rs2458431 c.1030-9T>C - t = 0.400/873
chr8 105367121 TM7SF4 SNP Het A G 48.78 1644 rs3802204 c.1046A>G p.Asp349Gly G = 0.1184/593
chr8 119941173 TNFRSF11B SNP Hom A G 99.93 1345 rs3134046 c.401-5T>C - A = 0.084/184
chr9 35060302 VCP SNP Het T C 52.71 848 rs684562 c.1695 + 8A>G - C = 0.427/932
chr9 35060955 VCP SNP Het T C 45.95 1049 rs2258240 c.1360-35A>G - t = 0.296/646
chr9 35062972 VCP SNP Het C T 46.47 2311 rs514492 c.811 + 3G>A - C = 0.297/649
chr9 35068201 VCP SNP Het C T 52.59 1274 rs10972300 c.129 + 47G>A - t = 0.155/339
chr10 13151224 OPTN SNP Het G A 45.83 144 rs2234968 c.102G>A p.Thr34 = A = 0.180/393
chr10 13152515 OPTN SNP Hom T G 98.85 611 rs79529484 c.369 + 39T>G - ?
chr10 13158262 OPTN SNP Het C T 36.58 1282 rs2244380 c.553-5C>T - C = 0.205/447
chr10 13164332 OPTN SNP Het T C 57.73 1275 rs765884 c.780-53T>C - C = 0.191/418
chr10 13167860 OPTN SNP Het G T 49.15 411 rs676302 c.1149-86G>T - G = 0.199/435
chr10 13174056 OPTN SNP Het T C 24.50 547 - c.1402-11T>C - -
chr13 43147671 N/A SNP Het T C 45.44 691 rs9533156 c.-149-620T>C - C = 0.457/999
chr13 43148024 N/A SNP Het T C 53.50 1415 rs9525641 c.-149-267T>C - C = 0.462/1009
chr13 43173198 N/A SNP Hom T C 99.68 937 rs3742257 c.388-1690T>C - t = 0.486/1062
chr18 60028821 TNFRSF11A SNP Het G T 20.75 877 rs35407865 c.617-92G>T - t = 0.151/330
chr18 60036083 TNFRSF11A SNP Hom A G 100.00 1187 rs8092336 c.730 + 7057A>G - A = 0.022/48
chr18 60051942 TNFRSF11A SNP Het G T 53.45 681 rs77857469 c.731-42G>T - t = 0.074/162
*maF – global minor allele frequency, the maF is actually the second most frequent allele value; SnP – single nucleotid polymorphism; hom – homozygous; het – 
heterozygous.
RECOOP for Common Mechanisms of Diseases 150 Croat Med J. 2015;56:145-51
www.cmj.hr
entirely clear and missing inheritance must play a signifi-
cant part in the pathogenesis of the disease. Our findings 
support this thesis.
In our patient we also showed a serious vitamin D deficien-
cy (1). The low level of vitamin D also increased the bone 
resorbing effect, leading to the worsening symptoms. Af-
ter prompt correction of the vitamin D level, while oral vi-
tamin D3 supplementation was continued at 2000 IU/d, it 
was possible to treat our patient with bisphosphonate.
Several trials (6,15) reported the use of anti-resoptive drugs 
for treatment of JPD. However, none of these treatments 
was able to normalize the markers of skeletal turnover (6). 
One of these drugs are bisphosphonates, which appear to 
be safe, even if used repeatedly over a long period of time 
(15). Cyclical intravenous pamidronate has been reported 
to normalize the serum ALP level (15), while in serious cas-
es lifelong anti-resoptive treatment may be necessary to 
control skeletal disease (1,16,17). Although Polyzos et al 
(18) described hypocalcaemia following response to zole-
dronate treatment in a JPD case, our patient did not have 
any side effect related to zoledronate treatment. After zole-
dronic acid treatment, her pain decreased and her quality 
of life also improved.
In conclusion, we showed that NGS technique can iden-
tify all the variants in several genes at the same time in a 
cost-effective manner. This is a new method for exploring 
the genetic background of juvenile Paget’s disease. We 
also showed that a severe vitamin D deficiency may com-
plicate the clinical picture, so it should be treated prior to 
anti-resorptive therapy. Zoledronic acid was used for bis-
phosphonate therapy, which makes this study the second 
report on the use of such medication for juvenile Paget’s 
disease. This therapy proved to be safe and effective in this 
rare skeletal disease.
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